SCHEMBL6035531

SCHEMBL6035531

CC(C)(Oc1ccc(OCCCCc2cc(-c3ccc(C(F)(F)F)cc3)no2)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.54
PPARD Q03181 11/20 0.54
PPARG P37231 11/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14269432 0.89 PPARD (0.45) PPARAPPARDPPARG
SCHEMBL14269423 0.88 PPARD (0.64) PPARAPPARDPPARG
SCHEMBL6034453 0.86 P2RY14 (0.52) PPARD
SCHEMBL14269455 0.86 PPARD (0.46) PPARAPPARDPPARG
SCHEMBL6034590 0.84 PPARD (0.49) PPARAPPARDPPARG
SCHEMBL6035565 0.83 FFAR1 (0.57) PPARAPPARDPPARG
SCHEMBL6034664 0.83 P2RY14 (0.53) PPARD
SCHEMBL14269472 0.82 PPARA (0.53) PPARAPPARDPPARG
SCHEMBL6035653 0.81 PPARD (0.50) PPARAPPARDPPARG
SCHEMBL6034613 0.80 FFAR1 (0.58) PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PPARA 1717/4885PPARD 2488/4885PPARG 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.